Skip to main content
Hybrigenics SA logo

Hybrigenics SA — Investor Relations & Filings

Ticker · ALHYG ISIN · FR0004153930 LEI · 9695003KQD0XMJYDX764 PA Professional, scientific and technical activities
Open in API
Filings indexed 145 across all filing types
Latest filing 2017-03-13 Earnings Release
Country FR France
Listing PA ALHYG

About Hybrigenics SA

https://www.hybrigenics-services.com/

Hybrigenics Services is a specialized provider of technologies for studying molecular interactions. Its core offering is the ULTImate Y2H™ platform, a comprehensive Yeast Two-Hybrid system used to discover protein-protein interactions, as well as interactions with DNA, RNA, and small molecules. This technology is applied to drug discovery for target deconvolution and identifying molecular glues. A second key service is the Hybribody platform, which leverages a proprietary synthetic library for the custom selection, validation, and optimization of single-domain antibodies (VHHs/Nanobodies). The company serves clients in fundamental research, pharmaceutical R&D, and agroscience.

Recent filings

Filing Released Lang Actions
Recentrage statégique sur la R&D biopharmaceutique
Earnings Release Classification · 98% confidence The document is a press release dated March 13, 2017, announcing a strategic repositioning (divesting a subsidiary, focusing on biopharma R&D) and simultaneously publishing key financial figures for the year 2016 (revenue and cash position as of December 31, 2016). This combination of announcing key financial results (revenue, cash position) for a period (2016) without being the full, comprehensive annual report (10-K) or a detailed management discussion (MDA) strongly suggests an Earnings Release (ER). It provides the highlights and context immediately following the period end, which is the primary function of an ER. FY 2016
2017-03-13 French
Résultats préliminaires encourageants de l’étude clinique de Phase II de l’inécalcitol dans la Leucémie Myéloïde Chronique
Regulatory Filings Classification · 95% confidence The document is titled with preliminary results ('Résultats préliminaires encourageants') regarding a Phase II clinical study for a drug (inécalcitol) in Chronic Myeloid Leukemia (CML). It details clinical trial progress, patient numbers, efficacy data (RMM, RMP), and includes quotes from medical experts and company management. The document concludes with sections labeled 'Communiqué de presse' (Press Release) and 'À propos d'Hybrigenics' (About Hybrigenics). This structure strongly indicates an official announcement of recent operational or clinical progress, which aligns best with an Earnings Release (ER) if it were quarterly results, or more generally, a type of corporate update. Since it is a detailed update on clinical trial progress rather than a formal financial statement (like 10-K or IR) or a general regulatory filing (RNS), and it is presented as a press release, it functions as a key operational update. Given the options, this type of announcement, which releases significant, time-sensitive operational news (clinical trial results), is often categorized as an Earnings Release (ER) if it accompanies financial reporting periods, or sometimes as a Regulatory Filing (RNS) if it's purely operational. However, because it is a detailed update on R&D progress and not a summary of financial performance metrics (revenue, profit, EPS), it is less likely to be a standard ER. It is a specific announcement of clinical data. In the absence of a specific 'Clinical Trial Update' code, and given that it is a formal announcement released to the public, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard disclosure, or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a news release. Given the context of providing key operational/scientific updates outside of mandatory financial reports, RNS is the most appropriate fallback for a press release detailing clinical progress.
2017-02-09 French
Le portefeuille de brevets d'Hybrigenics sur les inbihiteurs de protéases spécifiques de l'ubiquitine continue de s'agrandir
Regulatory Filings Classification · 95% confidence The document is a press release dated January 26, 2017, announcing the granting of patents related to Hybrigenics' ubiquitin-specific protease (USP) inhibitor portfolio in Europe, Japan, and the US. It details scientific progress, patent coverage, and company pipeline updates (inécalcitol). This type of announcement, focusing on corporate news, scientific milestones, or patent grants, is typically classified as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP) if it were a slide deck. However, given the structure (press release format, date, company boilerplate, contact info) and the nature of the announcement (patent grant/IP update), it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal, non-periodic disclosure that doesn't fit the specific financial report codes (10-K, IR, ER, MRQ). It is not a management report (MDA) or an earnings release (ER). Since it is a formal announcement of a corporate event/milestone, RNS is the most appropriate general regulatory disclosure code.
2017-01-26 French
Hybrigenics recrute le premier patient aux Etats-Unis dans l’étude clinique de l’inécalcitol dans la leucémie myéloïde aiguë chez des patients non-éligibles à la chimiothérapie
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Communiqué de presse' (Press Release) and announces a specific operational milestone: the recruitment of the first US patient in a Phase II clinical trial for a drug called inecalcitol in Acute Myeloid Leukemia (AML). This type of announcement, detailing clinical trial progress, is typically classified as an Earnings Release (ER) if it accompanies financial results, or more generally as a Regulatory Filing (RNS) if it's a standalone operational update. Since it is a press release announcing clinical trial progress rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA), and it doesn't fit the specific definitions for DVA, DIV, or CAP, the most appropriate general category for a significant, non-financial operational update released via press release is RNS (Regulatory Filings/General Regulatory Announcements). However, given the focus on clinical trial progress and the nature of biotech/pharma announcements, it strongly resembles an Earnings Release (ER) which often includes operational updates, or potentially a general Regulatory Filing (RNS). Since it is a press release announcing operational progress, and not a formal financial report, RNS is the safest general classification, although ER is often used for such updates in the pharma sector. Given the options, and the fact that it is a press release announcing a clinical milestone, RNS serves as the best fit for a general regulatory/operational announcement not covered by other specific codes.
2016-11-28 French
Hybrigenics présentera de nouveaux résultats in vitro sur l'inécalcitol dans le myélome multiple et dans la leucémie myéloïde aiguë au congrès annuel de l'ASH à San Diego, aux Etats-Unis
Regulatory Filings Classification · 90% confidence The document is a press release ("Communiqué de presse") dated November 3, 2016, announcing that Hybrigenics will present new *in vitro* results regarding its compound inecalcitol at the upcoming American Society of Hematology (ASH) annual congress in San Diego. This is an announcement about scientific data being presented at a conference, not the full financial report (10-K), an interim report (IR), or a formal earnings release (ER). It is a specific type of corporate communication detailing research progress and upcoming presentation. Since it is an announcement about scientific/research findings and presentation at a medical conference, it does not fit perfectly into the standard financial filing codes. However, it is a general corporate update/announcement. Given the options, it is closest to a general Regulatory Filing (RNS) as a fallback, or potentially an Investor Presentation (IP) if the content were the presentation itself, but here it is the *announcement* of the presentation. Since it is a press release detailing research progress and an upcoming presentation, and does not fit the specific financial report categories, RNS (Regulatory Filings / General regulatory announcements) is the most appropriate general classification for non-standard corporate news releases.
2016-11-03 French
Hybrigenics et Servier atteignent une nouvelle étape dans leur partenariat de recherche et développement
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific business event: Hybrigenics receiving a milestone payment (€1.5M) from Servier due to achieving a research and development milestone in their partnership. This type of announcement, detailing financial events, partnerships, or operational updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general corporate news. Since it is not a formal Earnings Release (ER), a Capital/Financing Update (CAP), or a specific regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), the most appropriate general category for a press release detailing a business development milestone payment is the fallback category, Regulatory Filings (RNS), as it serves as a general regulatory/corporate announcement.
2016-10-10 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.